- Home
- LIXT vs RBOT Comparison
LIXT vs RBOT Comparison
Compare LIXT & RBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- RBOT
- Stock Information
- Founded
- LIXT 2005
- RBOT 2014
- Country
- LIXT United States
- RBOT United States
- Employees
- LIXT N/A
- RBOT 131
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- RBOT Medical Specialities
- Sector
- LIXT Health Care
- RBOT Health Care
- Exchange
- LIXT Nasdaq
- RBOT Nasdaq
- Market Cap
- LIXT 20.5M
- RBOT 17.0M
- IPO Year
- LIXT N/A
- RBOT N/A
- Fundamental
- Price
- LIXT $4.00
- RBOT $2.53
- Analyst Decision
- LIXT
- RBOT Hold
- Analyst Count
- LIXT 0
- RBOT 1
- Target Price
- LIXT N/A
- RBOT $7.00
- AVG Volume (30 Days)
- LIXT 86.0K
- RBOT 80.9K
- Earning Date
- LIXT 11-12-2025
- RBOT 11-12-2025
- Dividend Yield
- LIXT N/A
- RBOT N/A
- EPS Growth
- LIXT N/A
- RBOT N/A
- EPS
- LIXT N/A
- RBOT N/A
- Revenue
- LIXT N/A
- RBOT N/A
- Revenue This Year
- LIXT N/A
- RBOT N/A
- Revenue Next Year
- LIXT N/A
- RBOT N/A
- P/E Ratio
- LIXT N/A
- RBOT N/A
- Revenue Growth
- LIXT N/A
- RBOT N/A
- 52 Week Low
- LIXT $0.64
- RBOT $2.44
- 52 Week High
- LIXT $6.26
- RBOT $19.00
- Technical
- Relative Strength Index (RSI)
- LIXT 41.53
- RBOT 23.28
- Support Level
- LIXT $4.14
- RBOT $2.44
- Resistance Level
- LIXT $4.49
- RBOT $3.18
- Average True Range (ATR)
- LIXT 0.42
- RBOT 0.44
- MACD
- LIXT 0.00
- RBOT -0.11
- Stochastic Oscillator
- LIXT 34.03
- RBOT 2.19
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.